Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an update.
Proteomics International Laboratories Ltd has received a $500,000 grant from the Western Australian Government to support the commercialization of PromarkerEndo, a pioneering blood test for diagnosing endometriosis. This funding will aid in regulatory, marketing, and partnership efforts, addressing the global health challenge of endometriosis, which affects one in nine women. The test offers a non-invasive alternative to current diagnostic methods, potentially transforming women’s healthcare by reducing the average seven-year diagnosis time, and is expected to launch in Australia in the second half of 2025.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services. The company focuses on proteomics, the large-scale study of proteins, and aims to enhance healthcare through innovative diagnostic tools.
Average Trading Volume: 338,131
Technical Sentiment Signal: Sell
Current Market Cap: A$53.2M
For a thorough assessment of PIQ stock, go to TipRanks’ Stock Analysis page.